Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABUS Arbutus Biopharma	$3.37	$3.31	$2.70 ▼ $4.72	$646.03M	0.86	636,487 shs	762,402 shs
DNTH Dianthus Therapeutics	$20.74 +2.4%	$19.49	$13.36 ▼ $32.27	$667.58M	1.43	337,294 shs	280,117 shs
LYEL Lyell Immunopharma	$10.58 -1.7%	$10.25	$7.65 ▼ $32.40	$206.71M	-0.19	71,908 shs	30,659 shs
PROK ProKidney	$2.36 -2.5%	$2.14	$0.46 ▼ $7.13	$708.33M	1.76	3.38 million shs	2.04 million shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABUS Arbutus Biopharma	0.00%	-0.88%	+7.67%	+9.42%	-8.42%
DNTH Dianthus Therapeutics	+2.42%	+10.55%	+4.54%	+5.33%	-27.23%
LYEL Lyell Immunopharma	-1.67%	-3.64%	+11.02%	+27.47%	-55.92%
PROK ProKidney	-2.48%	-8.67%	-36.73%	+192.59%	+3.51%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABUS Arbutus Biopharma	2.617 of 5 stars	3.5	1.0	3.1	2.5	0.6
DNTH Dianthus Therapeutics	1.3275 of 5 stars	3.5	0.0	2.4	0.8	0.0
LYEL Lyell Immunopharma	3.294 of 5 stars	2.8	5.0	1.0	4.2	1.3
PROK ProKidney	3.2508 of 5 stars	3.2	4.0	2.6	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABUS Arbutus Biopharma	3.00	Buy	$5.50	63.20% Upside
DNTH Dianthus Therapeutics	3.00	Buy	$53.00	155.54% Upside
LYEL Lyell Immunopharma	1.50	Reduce	$15.00	41.78% Upside
PROK ProKidney	2.40	Hold	$6.25	164.83% Upside

Current Analyst Ratings Breakdown

Latest LYEL, ABUS, DNTH, and PROK Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/11/2025	ABUS Arbutus Biopharma	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$5.00
7/15/2025	PROK ProKidney	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$4.00 ➝ $8.00
7/14/2025	PROK ProKidney	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $7.00
7/9/2025	PROK ProKidney	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$6.00 ➝ $9.00
7/2/2025	DNTH Dianthus Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
6/30/2025	PROK ProKidney	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Neutral ➝ Underperform	$3.00 ➝ $1.00
6/24/2025	LYEL Lyell Immunopharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$10.00

(Data available from 8/16/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABUS Arbutus Biopharma	$15.42M	41.91	N/A	N/A	$0.43 per share	7.84
DNTH Dianthus Therapeutics	$4.85M	137.53	N/A	N/A	$9.42 per share	2.20
LYEL Lyell Immunopharma	$60K	3,387.36	N/A	N/A	$15.56 per share	0.68
PROK ProKidney	$80K	8,634.65	N/A	N/A	($3.42) per share	-0.69

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABUS Arbutus Biopharma	-$69.92M	-$0.29	N/A	N/A	N/A	-352.24%	-59.28%	-44.11%	N/A
DNTH Dianthus Therapeutics	-$84.97M	-$3.25	N/A	N/A	N/A	-2,364.56%	-34.72%	-32.72%	N/A
LYEL Lyell Immunopharma	-$342.99M	-$24.29	N/A	N/A	N/A	-552,328.31%	-85.58%	-68.85%	N/A
PROK ProKidney	-$61.19M	-$0.57	N/A	N/A	N/A	N/A	N/A	-17.11%	N/A

Latest LYEL, ABUS, DNTH, and PROK Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	LYEL Lyell Immunopharma	-$3.80	-$2.89	+$0.91	-$2.89	$0.00 million	$0.01 million
8/12/2025	Q2 2025	PROK ProKidney	-$0.14	-$0.13	+$0.01	-$0.13	N/A	$0.22 million
8/7/2025	Q2 2025	DNTH Dianthus Therapeutics	-$0.86	-$0.88	-$0.02	-$0.88	$0.87 million	$0.19 million
8/6/2025	Q2 2025	ABUS Arbutus Biopharma	-$0.02	$0.01	+$0.03	$0.01	$2.21 million	$10.74 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABUS Arbutus Biopharma	N/A	N/A	N/A	N/A	N/A
DNTH Dianthus Therapeutics	N/A	N/A	N/A	N/A	N/A
LYEL Lyell Immunopharma	N/A	N/A	N/A	N/A	N/A
PROK ProKidney	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABUS Arbutus Biopharma	N/A	20.53	20.53
DNTH Dianthus Therapeutics	N/A	13.12	15.99
LYEL Lyell Immunopharma	N/A	7.65	7.49
PROK ProKidney	N/A	11.48	10.96

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABUS Arbutus Biopharma	43.79%
DNTH Dianthus Therapeutics	47.53%
LYEL Lyell Immunopharma	66.05%
PROK ProKidney	51.59%

Insider Ownership

Company	Insider Ownership
ABUS Arbutus Biopharma	20.30%
DNTH Dianthus Therapeutics	8.15%
LYEL Lyell Immunopharma	22.30%
PROK ProKidney	41.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABUS Arbutus Biopharma	90	191.70 million	152.78 million	Optionable
DNTH Dianthus Therapeutics	80	32.19 million	29.57 million	Optionable
LYEL Lyell Immunopharma	270	19.21 million	14.93 million	Optionable
PROK ProKidney	3	292.70 million	171.26 million	Optionable

LYEL, ABUS, DNTH, and PROK Headlines

Recent News About These Companies

ProKidney (NASDAQ:PROK) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

August 15 at 5:37 PM | marketbeat.com

ProKidney Reports 78 Percent Gain in Q2

August 14 at 10:16 PM | theglobeandmail.com

Citi Reaffirms Their Buy Rating on ProKidney (PROK)

August 14 at 10:16 PM | theglobeandmail.com

ProKidney reports larger second-quarter loss as key studies continue

August 14 at 10:16 PM | journalnow.comJ

ProKidney Corp. Reports Q2 2025 Financial Results

August 13 at 7:12 AM | msn.com

ProKidney reports Q2 EPS (13c), consensus (14c)

August 12, 2025 | msn.com

ProKidney Reports Second Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

August 12, 2025 | globenewswire.com

ProKidney Corp. (NASDAQ:PROK) Receives Consensus Rating of "Hold" from Analysts

August 10, 2025 | marketbeat.com

ProKidney Corp. (PROK) - Yahoo Finance

August 9, 2025 | finance.yahoo.com

ProKidney Corp. (NASDAQ:PROK) Given Average Recommendation of "Hold" by Brokerages

August 9, 2025 | americanbankingnews.com

ProKidney And 2 Other Penny Stocks To Watch Closely

August 7, 2025 | finance.yahoo.com

ProKidney (NASDAQ:PROK) Trading Down 10.5% - What's Next?

August 7, 2025 | marketbeat.com

ProKidney (NASDAQ:PROK) Stock Price Up 10% - Should You Buy?

August 1, 2025 | marketbeat.com

ProKidney (PROK) to Release Quarterly Earnings on Friday

August 1, 2025 | marketbeat.com

ProKidney (NASDAQ:PROK) Stock Price Down 7.8% - What's Next?

July 29, 2025 | marketbeat.com

ProKidney Stock Skyrockets But Greensboro Is Still Empty Handed

July 25, 2025 | rhinotimes.comR

ProKidney Corp (PROK) Completes Re-domestication to Delaware amid Kidney Therapy Advancement

July 22, 2025 | msn.com

Meet the Biotech Stock That Rocketed 775% Higher

July 22, 2025 | fool.com

ProKidney (NASDAQ:PROK) Shares Gap Up - Here's Why

July 21, 2025 | marketbeat.com

JP Morgan Maintains a Neutral Stance on ProKidney Corp. (PROK)

July 20, 2025 | insidermonkey.com

ProKidney (NASDAQ:PROK) Shares Down 4.1% - Time to Sell?

July 18, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LYEL, ABUS, DNTH, and PROK Company Descriptions

Arbutus Biopharma NASDAQ:ABUS

$3.37 0.00 (0.00%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$3.32 -0.06 (-1.63%)

As of 08/15/2025 07:59 PM Eastern

Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of imdusiran (AB-729), a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Barinthus Biotherapeutics plc to evaluate VTP-300. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Dianthus Therapeutics NASDAQ:DNTH

$20.74 +0.49 (+2.42%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$20.60 -0.14 (-0.68%)

As of 08/15/2025 07:11 PM Eastern

Dianthus Therapeutics, Inc., a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc. was founded in 2019 and is headquartered in New York, New York.

Lyell Immunopharma NASDAQ:LYEL

$10.58 -0.18 (-1.67%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$10.57 -0.01 (-0.09%)

As of 08/15/2025 05:51 PM Eastern

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.

ProKidney NASDAQ:PROK

$2.36 -0.06 (-2.48%)

Closing price 08/15/2025 04:00 PM Eastern

Extended Trading

$2.38 +0.02 (+0.64%)

As of 08/15/2025 07:58 PM Eastern

ProKidney Corp., a clinical-stage biotechnology company, provides transformative proprietary cell therapy platform for treating various chronic kidney diseases in the United States. The company's lead product is Renal Autologous Cell Therapy (REACT), an autologous homologous cell admixture, which has completed Phase I clinical trial for REACT in patients with congenital anomalies of the Kidney and Urinary Tract (CAKUT), as well as in Phase III and Phase II clinical trials for the treatment of moderate to severe diabetic kidney disease. ProKidney Corp. founded in 2015 and is headquartered in Winston-Salem, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time